Migalastat Chaperone Dosing for Fabry Cardiac and GL-3 Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Fabry disease have limitations, including slow cardiac muscle response and limited GL-3 elimination from kidney cells, with some patients developing immune reactions, necessitating the need for alternative therapeutic approaches.
Innovation Solution
Administration of migalastat or its salt every other day, in effective amounts, enhances α-Gal A activity, reducing left ventricular mass index (LVMi) and addressing GL-3 accumulation in patients with Fabry disease, including those naive or experienced with enzyme replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered to treat Fabry disease, then α-Gal A activity is supplemented, but the treatment shows slow cardiac muscle response and limited GL-3 elimination from kidney cells
Solution Approach 1:
The patent changes the therapeutic approach from enzyme replacement to pharmacological chaperone therapy using migalastat, which stabilizes and enhances the activity of mutant α-Gal A enzymes. This parameter change in treatment mechanism achieves faster cardiac response and improved GL-3 elimination compared to ERT
Solution Approach 2:
Migalastat acts as a pharmacological chaperone intermediary that binds to mutant α-Gal A enzymes, stabilizing their structure and enhancing their catalytic activity. This intermediary approach allows the body's own enzymes to function more effectively, producing faster therapeutic responses than external enzyme replacement
2Reliability
If enzyme replacement therapy (ERT) is administered to treat Fabry disease, then substrate accumulation is addressed, but some patients develop immune reactions
Solution Approach 1:
Migalastat serves as a pharmacological chaperone that works with the patient's own mutant enzymes rather than introducing foreign proteins. This intermediary approach enhances endogenous enzyme activity without triggering the immune responses that occur with exogenous enzyme replacement therapy
Solution Approach 2:
The treatment enables the patient's own mutant α-Gal A enzymes to function effectively through pharmacological chaperoning, rather than relying on external enzyme administration. This self-service approach uses the body's own biological systems, avoiding immune rejection of foreign proteins
3Reliability
If migalastat is administered to enhance α-Gal A activity, then left ventricular mass index decreases significantly, but the treatment requires consistent every-other-day dosing
Solution Approach 1:
Migalastat is administered on an every-other-day periodic schedule, which maintains therapeutic levels of the pharmacological chaperone while allowing metabolic clearance cycles. This periodic dosing achieves sustained cardiac parameter normalization while being more convenient than daily administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Migalastat significantly decreases LVMi by 5-20.8 g/m² over 18-36 months, normalizes cardiac parameters, and reduces GL-3 inclusion volume and podocyte volume by 30-50% within 6 months, providing effective treatment for Fabry disease.
Implementation Method 1
migalastat or salt thereof for use in a method of treating Fabry disease... wherein the migalastat or salt thereof enhances α-Gal A activity
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naive Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.